Metavia (NRBO) | Financial Analysis & Statements
Metavia Inc. Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2024Income Metrics
Revenue
0
Operating Income
-6.3M
Net Income
-5.7M
EPS (Diluted)
$-0.55
Balance Sheet Metrics
Total Assets
22.1M
Total Liabilities
9.2M
Shareholders Equity
13.0M
Debt to Equity
0.71
Cash Flow Metrics
Operating Cash Flow
-6.9M
Free Cash Flow
-5.6M
Revenue & Profitability Trend
Metavia Income Statement From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 9.2M | 2.8M | 6.5M | 21.9M | 17.5M |
| Selling, General & Administrative | 6.7M | 8.6M | 8.8M | 7.8M | 2.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 15.9M | 11.4M | 15.3M | 29.7M | 20.2M |
| Operating Income | -15.9M | -11.4M | -15.3M | -29.7M | -20.2M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 461.0K | 0 | 14.0K | 39.0K | - |
| Interest Expense | 0 | 2.2M | 0 | - | - |
| Other Non-Operating Income | 3.0M | -358.0K | - | -1.0K | -1.1M |
| Pre-tax Income | -12.5M | -14.0M | -15.3M | -29.7M | -21.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -12.5M | -14.0M | -15.3M | -29.7M | -21.3M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -15.4M | -11.5M | -15.2M | -29.7M | -19.0M |
| EPS (Basic) | $-2.46 | $-125.98 | $-158.40 | $-439.20 | $-979.20 |
| EPS (Diluted) | $-2.46 | $-125.98 | $-158.40 | $-439.20 | $-979.20 |
| Basic Shares Outstanding | 5071101 | 110932 | 96432 | 67572 | 21767 |
| Diluted Shares Outstanding | 5071101 | 110932 | 96432 | 67572 | 21767 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Metavia Balance Sheet From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 22.4M | 33.4M | 16.4M | 10.1M | 13.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 77.0K | 168.0K | - | 48.0K | 42.0K |
| Total Current Assets | 22.5M | 33.5M | 16.6M | 10.7M | 14.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 202.0K | - | 263.0K | 288.0K | 308.0K |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 21.0K | - | - | - | - |
| Total Non-Current Assets | 269.0K | 2.0K | 215.0K | 285.0K | 350.0K |
| Total Assets | 22.8M | 33.5M | 16.8M | 11.0M | 14.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 821.0K | 708.0K | 830.0K | 2.6M | 638.0K |
| Short-term Debt | 67.0K | - | 26.0K | 24.0K | 22.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 658.0K | 10.8M | - | - | - |
| Total Current Liabilities | 6.0M | 11.8M | 2.2M | 3.7M | 2.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 136.0K | 0 | 45.0K | 70.0K | 94.0K |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 136.0K | 0 | 45.0K | 70.0K | 94.0K |
| Total Liabilities | 6.1M | 11.8M | 2.2M | 3.8M | 2.2M |
| Equity | |||||
| Common Stock | 5.0K | 25.0K | 1.0K | 20.0K | 16.0K |
| Retained Earnings | -108.3M | -95.8M | -81.8M | -66.5M | -36.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 16.7M | 21.8M | 14.6M | 7.2M | 12.3M |
| Key Metrics | |||||
| Total Debt | 203.0K | 0 | 71.0K | 94.0K | 116.0K |
| Working Capital | 16.6M | 21.7M | 14.4M | 7.0M | 12.0M |
Balance Sheet Composition
Metavia Cash Flow Statement From 2019 to 2023
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -12.5M | -14.0M | -15.3M | -29.7M | -21.3M |
| Depreciation & Amortization | 6.0K | 20.0K | 48.0K | 46.0K | 17.0K |
| Stock-Based Compensation | 222.0K | 854.0K | 662.0K | 699.0K | 118.0K |
| Working Capital Changes | 113.0K | -202.0K | -1.2M | 1.1M | -1.0M |
| Operating Cash Flow | -12.1M | -5.1M | -15.7M | -10.4M | -9.9M |
| Investing Activities | |||||
| Capital Expenditures | -50.0K | 8.0K | -3.0K | -4.0K | -214.0K |
| Acquisitions | - | - | - | 180.0K | 1.5M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -50.0K | 8.0K | -586.0K | 249.0K | -6.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -80.0K | 28.7M | 21.9M | 6.8M | 24.2M |
| Free Cash Flow | -10.8M | -11.7M | -15.1M | -10.8M | -7.3M |
| Net Change in Cash | -12.3M | 23.6M | 5.6M | -3.4M | 8.2M |
Cash Flow Trend
Metavia Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.97
Forward P/E
-1.39
Price to Book
1.57
PEG Ratio
-1.39
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-160.76%
Return on Assets
-74.35%
Financial Health
Current Ratio
2.41
Debt to Equity
1.19
Beta
-0.28
Per Share Data
EPS (TTM)
$-4.29
Book Value per Share
$1.51
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NRBO | 20.3M | 12.97 | 1.57 | -160.76% | 0.00% | 1.19 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Royalty Pharma plc | 29.4B | 27.89 | 3.29 | 13.20% | 32.42% | 92.33 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
Financial data is updated regularly. All figures are in the company's reporting currency.